Andrew Yee, MD
@andrew02114
Medical oncologist at @MGHCancerCenter, Asst. Prof. of Medicine @harvardmed, focusing on patient care and trials in multiple myeloma and plasma cell disorders.
You might like
Super useful table by @bdermanmd for benchmarking depth of response with induction therapy, especially as trials in newly diagnosed MM are starting to include anti-BCMA therapies which may take things further.
7500 – MIDAS Trial: MRD-Guided Therapy Post-IsaKRd 718 NDMM pts. After Isa-KRd x6, 67% were MRD− at 10⁻⁵. Randomized to continue Isa-KRd x 6 or go to ASCT prior to maintenance. No difference in MRD<10⁻6 (84% vs 86%) thus far! And as for MRD(+) post-induction: no difference…
Subcutaneous isatuximab is on the horizon! Press release on phase 3 IRAKLIA study shows s.c. similar to i.v. (as would be expected). Hopefully this will enable approval and availability of s.c. isatuximab soon! sanofi.com/en/media-room/…
This was a very practical poster at #ASH24, looking at prolonged dosing intervals of teclistamab, which is very relevant as dosing of tec (and other bispecific antibodies) moves to q4 week (or even longer intervals). New recommendation: if dosing interval ≤62 days, no need to…
Joining in for #ASHaiku #ASH24 In San Diego, friends gather, sharing new hope for myeloma (with some assistance from ChatGPT 😀)
☀️ Awaken your inner poet and write your best haiku about #ASH24 or #hematology! That's 3 lines in a 5-7-5 syllable pattern. Post now through Tuesday afternoon and include #ASHaiku. You might get included in a highlights post! 🛑Remember, there's only one H in #ASHaiku!
An ATLAS to map MRD with peripheral blood: a nice editorial on mass spec in MM #mmsm #bmtsm @andrew02114 ashpublications.org/blood/article/…
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection | Blood Cancer Journal @andrew02114 nature.com/articles/s4140…
Thanks @RahulBanerjeeMD! We're looking forward to presenting the poster at ASCO. Excellent outcomes when using daratumumab combinations upfront for patients hospitalized with acute kidney injury (including on dialysis) from myeloma. And this is without plasmapheresis.
10/ #ASCO24 #MMsm abstracts: Abstract #7525 (Kim et al): Renal recovery with inpatient dara for acute cast nephropathy. Median time to ≥50% LC reduction with 🏥 dara (e.g. D-CyBorD) only 3 days. Inpatient dara cheaper & easier than PLEX, right?? meetings.asco.org/abstracts-pres…
The ODAC on 3/15/24 on cilta-cel and ide-cel was like a plenary or late breaking abstracts session at ASH along with elements of America’s Got Talent. Lots of data being presented, discussion and analysis, and voting too!
United States Trends
- 1. Texas A&M 12.1K posts
- 2. South Carolina 12.7K posts
- 3. Marcel Reed 2,446 posts
- 4. Aggies 3,626 posts
- 5. Nyck Harbor 1,257 posts
- 6. College Station 1,929 posts
- 7. Jeremiyah Love 3,144 posts
- 8. Elko 2,266 posts
- 9. Malachi Fields 1,349 posts
- 10. Mike Shula N/A
- 11. Dylan Stewart N/A
- 12. Shane Beamer N/A
- 13. #GoIrish 2,992 posts
- 14. Sellers 10.2K posts
- 15. Michigan 41.9K posts
- 16. TAMU 5,682 posts
- 17. Northwestern 4,266 posts
- 18. Zvada N/A
- 19. Randy Bond N/A
- 20. Sherrone Moore N/A
You might like
-
Tom Martin
@TomBmt133 -
Gareth Morgan
@DrGarethMorgan1 -
Suzanne Lentzsch, MD, PhD
@SLentzsch -
Joseph Mikhael
@jmikhaelmd -
Sagar Lonial MD
@SagarLonialMD -
Ajay Nooka, MD, MPH
@AjayNookaMD -
Daniel Auclair
@AuclairDan -
Luciano J Costa
@End_myeloma -
Noopur Raje
@NoopurRajeMD -
Krina Patel
@DrKrinaPatel -
Craig Hofmeister
@EagleMyeloma -
Joshua Richter, MD, FACP
@JoshuaRichterMD -
Rafat Abonour
@rabonour1 -
Raj Chakraborty
@rajshekharucms -
Ben Derman
@bdermanmd
Something went wrong.
Something went wrong.